Immunotherapy and chemo for MHC-II positive stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This clinical trial tests whether adding an immunotherapy drug called tislelizumab to chemotherapy before surgery is better than chemotherapy alone for people with a certain type of stomach cancer. The goal is to see if the combination helps shrink the tumor and improves the chance of successful surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your cancer must be stomach (gastric) or gastroesophageal junction (GEJ) cancer, and it must have a specific marker called MHC-II (the doctor checks this with a test).
- The cancer must have spread to nearby lymph nodes but not to other parts of the body, and it must be possible to remove it with surgery.
- You cannot have had any previous treatment for this cancer (like surgery, chemo, or radiation).
- You must be healthy enough to receive treatment, with good blood counts, liver and kidney function, and be able to take oral medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immune therapy and chemotherapy given before surgery for stomach or esophagus-stomach cancer. The goal is to shrink the tumor to make surgery more effective and possibly improve outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether adding the immunotherapy drug Sintilimab to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It's for people with high-risk or advanced stage cancer that has a specific genetic feature (dMMR or MSI-H).
This trial tests a combination of an immunotherapy drug (PD-1 antibody) plus chemotherapy or targeted therapy, followed by surgery, for people with stomach cancer that has spread to a limited number of other sites. The goal is to see if this approach can help shrink the cancer enough to make surgery more effective.
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
This study tests a combination of an immunotherapy drug (tislelizumab) with two chemotherapy drugs (called the SOX regimen) given before surgery for locally advanced stomach cancer. The goal is to see if this treatment can shrink the tumor and make it easier to remove completely during surgery.
Hear when a new Gastric Cancer Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.